Cedric Francois, Apellis CEO (Optum via YouTube)

Apel­lis, Beam team up to test base edit­ing against the broad field of com­ple­ment dis­or­ders

Last sum­mer, as Apel­lis was prepar­ing for the ap­proval of its po­ten­tial block­buster PNH drug Em­paveli, CEO Cedric Fran­cois sat down with his team and be­gan plot­ting the post-Em­paveli fu­ture.

Apel­lis had spent most of its 12-year his­to­ry de­vel­op­ing that one drug. The pipeline list­ed on­line con­sist­ed of sev­en items, six of which were dif­fer­ent for­mu­la­tions or ap­pli­ca­tions of the mol­e­cule. But in 2018, they start­ed div­ing deep­er in­to com­ple­ment bi­ol­o­gy — the broad im­munol­o­gy sub-field where Em­paveli op­er­ates — in hopes of ex­pand­ing their reach.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.